Novel Treatments & Drugs

Vudalimab for the Treatment of Mesothelioma

The MD Anderson Cancer Center is conducting a study on an immunotherapy drug that is specifically for rare, advanced tumors. Pleural and peritoneal mesothelioma are both included in the study. The clinical trial is looking for effectiveness and safety of vudalimab. The treatment, also known as XmAb20717, was created by[…]

Read More »

Proton Beam Radiation Therapy Use Increases for Mesothelioma and Lung Cancer

Proton beam radiation therapy is growing in popularity for treating mesothelioma and lung cancer. A study in JAMA Oncology looked at the use of this radiation for treating different types of cancer. There were almost 6 million patients in the study and data shows that proton radiation use tripled from[…]

Read More »

Monoclonal Antibody Treatment was Found Not to be Effective on Pleural Mesothelioma

A phase II clinical trial comparing anetumab ravtansine to the chemotherapy drug vinorelbine did not have promising results for treating mesothelioma like researchers had hoped. Anetumab ravtansine is an immunotherapy drug that is a monoclonal antibody, which is an engineered antibody that can be used to fight cancer. Researchers found[…]

Read More »

High HITHOC Dosage for Pleural Mesothelioma Improves Survival

High doses of hyperthermic intrathoracic chemotherapy (HITHOC) help pleural mesothelioma patients. A recent study found that when HITHOC is administered at a high dose, survival rates improve and periods of being disease free increase. HITHOC is the use of chemotherapy during surgery and is an experimental treatment for different types[…]

Read More »

Platelet Count Can Potentially Influence Mesothelioma Survival

Mesothelioma is a hard-to-treat cancer. Usually chemotherapy, surgery, radiotherapy, and immunotherapy are used, but they do not do enough to save people’s lives. Scientists may have figured out why this is the case and could potentially have found the main causes that affect survival. These include stage of the tumor,[…]

Read More »

A Cancer Vaccine Could Potentially Help Mesothelioma Patients

Researchers are looking at a vaccine to maintain patient health after cancer treatment, which could be effective for mesothelioma in the future.  The vaccine is specifically made for each patient based on the individual’s biology. The trial is currently being tested on head and neck cancer. It does not usually[…]

Read More »

Researchers are Targeting Fibrosis to Improve Mesothelioma Care

Researchers have found that targeting lung fibrosis can help people with mesothelioma. People with mesothelioma usually suffer from fibrosis, which is the stiffening of tissue surrounding tumors. Certain drugs to treat mesothelioma are not very effective because the fibrosis prevents the drugs from penetrating the tumor. It also prevents the[…]

Read More »

OT-101 Useful for COVID-19 and Cancers Like Mesothelioma

Researchers are looking at a new treatment for mesothelioma. It is a multimodal treatment (multiple treatments combined) consisting of the immunotherapy drug Keytruda and a new drug called OT-101. OT-101 is an antisense drug, which is a drug that blocks molecules that make certain proteins. The drug is also effective[…]

Read More »

A Gene Therapy Could Improve Survival for Mesothelioma

Results from a new study involving a genetic therapy for pleural mesothelioma have been submitted at the University of Leicester. Researchers at the United Kingdom university designed a treatment to match specific genetic profiles to individual patients. There are promising results from the study, which had patients who received first[…]

Read More »

Tremelimumab and Durvalumab Combination Can Improve Mesothelioma Survival

Studies show that durvalumab and tremelimumab work very well together while treating mesothelioma. A phase I clinical trial was performed at the Baylor College of Medicine in conjunction with Baylor St. Luke’s Medical Center. Durvalumab is an immunotherapy drug known as a PD-1/PD-L1 checkpoint inhibitor. It works by blocking the[…]

Read More »